HESI RN PHARMACOLOGY PROCTORED EXAM - 2026/2027
EDITION - ORIGINAL HESI-STYLE PRACTICE QUESTIONS WITH
VERIFIED ANSWERS AND DETAILED CLINICAL RATIONALES
179 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
HESI RN PHARMACOLOGY PROCTORED EXAM - 2026/2027 EDITION - ORIGINAL HESI-STYLE PRACTICE
QUESTIONS WITH VERIFIED ANSWERS AND DETAILED CLINICAL RATIONALES. It contains 179 carefully
selected questions that reflect the most current exam content and testing strategies. Each question is
accompanied by a correct answer and a detailed rationale that explains the underlying pathophysiology,
pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 179 Questions
Foundations - Application - HESI RN Pharmacology Proctored 2026/2027 Edition Original Hesi-style WITH
AND Detailed Clinical Rationales Pharmacology FOR Registered Nurses Undergraduate YEAR 3 / Graduate
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
HESI RN Pharmacology 1-30 Prescribed, Explains, Effect, Appropriate, Receiving
Proctored 2026/2027 Edition
Original Hesi-style WITH AND
Detailed Clinical Rationales
Pharmacology FOR
Registered Nurses
Undergraduate YEAR 3 /
Graduate
Appropriate 31-60 Prescribed, Finding, Develops, Acute, Naloxone
Develops 61-90 Therapy, Started, Prescribed, Phenytoin, Interaction
Explains 91-120 Prescribed, Develops, Mechanism, Appropriate, Atrial Fibrillation
Therapy 121-150 Prescribed, Appropriate, Level, Develops, Requires
Requires 151-179 Prescribed, Digoxin, Appropriate, Develops, Medication
TOTAL 179 All questions include answers and detailed rationales
,Section A - HESI RN Pharmacology Proctored 2026/2027
Edition Original Hesi-style WITH AND Detailed Clinical
Rationales Pharmacology FOR Registered Nurses
Undergraduate YEAR 3 / Graduate
Q1.
A patient with chronic heart failure is initiated on sacubitril/valsartan. Which mechanism
best explains the synergistic effect of this combination?
A. Sacubitril inhibits neprilysin, increasing B. Sacubitril blocks angiotensin II type 1
natriuretic peptides, while valsartan blocks receptors, while valsartan inhibits neprilysin,
AT1 receptors, reducing aldosterone leading to vasodilation.
release.
C. Sacubitril inhibits ACE, while valsartan D. Sacubitril enhances bradykinin
blocks angiotensin II receptors, providing degradation, while valsartan promotes
dual blockade of the RAAS. sodium retention, balancing fluid volume.
Correct: A - Sacubitril inhibits neprilysin, increasing natriuretic peptides, while valsartan
blocks AT1 receptors, reducing aldosterone release.
Rationale:Sacubitril is a neprilysin inhibitor that increases natriuretic peptides (vasodilatory,
natriuretic), while valsartan is an ARB that blocks AT1 receptors, reducing aldosterone and
vasoconstriction. The combination (ARNI) provides complementary benefits. Option C is
incorrect because sacubitril does not inhibit ACE. Option B reverses the roles. Option D
misidentifies sacubitril's effect on bradykinin and valsartan's action.
Q2.
When administering intravenous vancomycin to a critically ill patient, which
pharmacokinetic parameter most requires individualized dosing to achieve efficacy while
minimizing toxicity?
A. Volume of distribution B. Area under the curve (AUC)
C. Half-life D. Bioavailability
Correct: B - Area under the curve (AUC)
Rationale:The AUC-to-MIC ratio is the primary pharmacodynamic target for vancomycin
efficacy, and AUC-guided dosing reduces acute kidney injury. While volume of distribution and
half-life influence loading and maintenance doses, AUC integrates these parameters and is
the key metric for individualized dosing. Bioavailability is irrelevant for IV administration. Thus,
B is correct.
Page 3
, Section A - HESI RN Pharmacology Proctored 2026/2027 Edition Original Hesi-style WITH AND Detailed Clinical Rationales Pharmacology FOR
Registered Nurses Undergraduate YEAR 3 / Graduate
Q3.
Which drug requires genetic testing before initiation to prevent severe hypersensitivity
reactions in patients of Asian ancestry?
A. Allopurinol B. Warfarin
C. Azathioprine D. Isoniazid
Correct: A - Allopurinol
Rationale:Allopurinol is associated with severe cutaneous adverse reactions (e.g.,
Stevens-Johnson syndrome) in patients carrying the HLA-B*58:01 allele, common in Han
Chinese and Thai populations; screening is recommended. Warfarin requires
CYP2C9/VKORC1 testing, azathioprine requires TPMT testing, and isoniazid is affected by
NAT2 acetylation status, but these do not typically cause HLA-linked hypersensitivity.
Therefore, A is correct.
Q4.
A patient receiving an aminoglycoside develops nephrotoxicity. Which cellular mechanism
primarily underlies this adverse effect?
A. Inhibition of cyclooxygenase-1 in renal B. Accumulation in proximal tubular cells
medulla leading to phospholipidosis and
mitochondrial dysfunction
C. Blockade of aldosterone receptors in D. Induction of cytochrome P450 enzymes
distal tubule increasing toxic metabolites
Correct: B - Accumulation in proximal tubular cells leading to phospholipidosis and
mitochondrial dysfunction
Rationale:Aminoglycosides accumulate in proximal tubular epithelial cells via
megalin-mediated endocytosis, causing phospholipidosis, mitochondrial injury, and apoptosis,
leading to nonoliguric renal failure. They do not inhibit COX-1 (NSAIDs), block aldosterone
receptors (spironolactone), or induce CYP450s. Thus, B is correct.
Q5.
Which medication should be held 48 hours before and after administration of a
radioiodine (I-131) scan for thyroid cancer surveillance?
A. Levothyroxine B. Methimazole
C. Liothyronine D. Potassium iodide
Correct: C - Liothyronine
Page 4
EDITION - ORIGINAL HESI-STYLE PRACTICE QUESTIONS WITH
VERIFIED ANSWERS AND DETAILED CLINICAL RATIONALES
179 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
HESI RN PHARMACOLOGY PROCTORED EXAM - 2026/2027 EDITION - ORIGINAL HESI-STYLE PRACTICE
QUESTIONS WITH VERIFIED ANSWERS AND DETAILED CLINICAL RATIONALES. It contains 179 carefully
selected questions that reflect the most current exam content and testing strategies. Each question is
accompanied by a correct answer and a detailed rationale that explains the underlying pathophysiology,
pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 179 Questions
Foundations - Application - HESI RN Pharmacology Proctored 2026/2027 Edition Original Hesi-style WITH
AND Detailed Clinical Rationales Pharmacology FOR Registered Nurses Undergraduate YEAR 3 / Graduate
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
HESI RN Pharmacology 1-30 Prescribed, Explains, Effect, Appropriate, Receiving
Proctored 2026/2027 Edition
Original Hesi-style WITH AND
Detailed Clinical Rationales
Pharmacology FOR
Registered Nurses
Undergraduate YEAR 3 /
Graduate
Appropriate 31-60 Prescribed, Finding, Develops, Acute, Naloxone
Develops 61-90 Therapy, Started, Prescribed, Phenytoin, Interaction
Explains 91-120 Prescribed, Develops, Mechanism, Appropriate, Atrial Fibrillation
Therapy 121-150 Prescribed, Appropriate, Level, Develops, Requires
Requires 151-179 Prescribed, Digoxin, Appropriate, Develops, Medication
TOTAL 179 All questions include answers and detailed rationales
,Section A - HESI RN Pharmacology Proctored 2026/2027
Edition Original Hesi-style WITH AND Detailed Clinical
Rationales Pharmacology FOR Registered Nurses
Undergraduate YEAR 3 / Graduate
Q1.
A patient with chronic heart failure is initiated on sacubitril/valsartan. Which mechanism
best explains the synergistic effect of this combination?
A. Sacubitril inhibits neprilysin, increasing B. Sacubitril blocks angiotensin II type 1
natriuretic peptides, while valsartan blocks receptors, while valsartan inhibits neprilysin,
AT1 receptors, reducing aldosterone leading to vasodilation.
release.
C. Sacubitril inhibits ACE, while valsartan D. Sacubitril enhances bradykinin
blocks angiotensin II receptors, providing degradation, while valsartan promotes
dual blockade of the RAAS. sodium retention, balancing fluid volume.
Correct: A - Sacubitril inhibits neprilysin, increasing natriuretic peptides, while valsartan
blocks AT1 receptors, reducing aldosterone release.
Rationale:Sacubitril is a neprilysin inhibitor that increases natriuretic peptides (vasodilatory,
natriuretic), while valsartan is an ARB that blocks AT1 receptors, reducing aldosterone and
vasoconstriction. The combination (ARNI) provides complementary benefits. Option C is
incorrect because sacubitril does not inhibit ACE. Option B reverses the roles. Option D
misidentifies sacubitril's effect on bradykinin and valsartan's action.
Q2.
When administering intravenous vancomycin to a critically ill patient, which
pharmacokinetic parameter most requires individualized dosing to achieve efficacy while
minimizing toxicity?
A. Volume of distribution B. Area under the curve (AUC)
C. Half-life D. Bioavailability
Correct: B - Area under the curve (AUC)
Rationale:The AUC-to-MIC ratio is the primary pharmacodynamic target for vancomycin
efficacy, and AUC-guided dosing reduces acute kidney injury. While volume of distribution and
half-life influence loading and maintenance doses, AUC integrates these parameters and is
the key metric for individualized dosing. Bioavailability is irrelevant for IV administration. Thus,
B is correct.
Page 3
, Section A - HESI RN Pharmacology Proctored 2026/2027 Edition Original Hesi-style WITH AND Detailed Clinical Rationales Pharmacology FOR
Registered Nurses Undergraduate YEAR 3 / Graduate
Q3.
Which drug requires genetic testing before initiation to prevent severe hypersensitivity
reactions in patients of Asian ancestry?
A. Allopurinol B. Warfarin
C. Azathioprine D. Isoniazid
Correct: A - Allopurinol
Rationale:Allopurinol is associated with severe cutaneous adverse reactions (e.g.,
Stevens-Johnson syndrome) in patients carrying the HLA-B*58:01 allele, common in Han
Chinese and Thai populations; screening is recommended. Warfarin requires
CYP2C9/VKORC1 testing, azathioprine requires TPMT testing, and isoniazid is affected by
NAT2 acetylation status, but these do not typically cause HLA-linked hypersensitivity.
Therefore, A is correct.
Q4.
A patient receiving an aminoglycoside develops nephrotoxicity. Which cellular mechanism
primarily underlies this adverse effect?
A. Inhibition of cyclooxygenase-1 in renal B. Accumulation in proximal tubular cells
medulla leading to phospholipidosis and
mitochondrial dysfunction
C. Blockade of aldosterone receptors in D. Induction of cytochrome P450 enzymes
distal tubule increasing toxic metabolites
Correct: B - Accumulation in proximal tubular cells leading to phospholipidosis and
mitochondrial dysfunction
Rationale:Aminoglycosides accumulate in proximal tubular epithelial cells via
megalin-mediated endocytosis, causing phospholipidosis, mitochondrial injury, and apoptosis,
leading to nonoliguric renal failure. They do not inhibit COX-1 (NSAIDs), block aldosterone
receptors (spironolactone), or induce CYP450s. Thus, B is correct.
Q5.
Which medication should be held 48 hours before and after administration of a
radioiodine (I-131) scan for thyroid cancer surveillance?
A. Levothyroxine B. Methimazole
C. Liothyronine D. Potassium iodide
Correct: C - Liothyronine
Page 4
